Kumar Ramesh, Anand Utpal, Priyadarshi Rajeev Nayan
Department of Gastroenterology, All India Institute of Medical Sciences, Patna 801507, Bihar, India.
Department of Surgical Gastroenterology, All India Institute of Medical Sciences, Patna 801507, Bihar, India.
World J Transplant. 2021 Jun 18;11(6):187-202. doi: 10.5500/wjt.v11.i6.187.
Acute liver failure (ALF) refers to a state of severe hepatic injury that leads to altered coagulation and sensorium in the absence of pre-existing liver disease. ALF has different causes, but the clinical characteristics are strikingly similar. In clinical practice, however, inconsistency in the definition of ALF worldwide and confusion regarding the existence of pre-existing liver disease raise diagnostic dilemmas. ALF mortality rates used to be over 80% in the past; however, survival rates on medical treatment have significantly improved in recent years due to a greater understanding of pathophysiology and advances in critical care management. The survival rates in acetaminophen-associated ALF have become close to the post-transplant survival rates. Given that liver transplantation (LT) is an expensive treatment that involves a major surgical operation in critically ill patients and lifelong immunosuppression, it is very important to select accurate patients who may benefit from it. Still, emergency LT remains a lifesaving procedure for many ALF patients. However, there is a lack of consistency in current prognostic models that hampers the selection of transplant candidates in a timely and precise manner. The other problems associated with LT in ALF are the shortage of graft, development of contraindications on the waiting list, vaguely defined delisting criteria, time constraints for pre-transplant evaluation, ethical concerns, and comparatively poor post-transplant outcomes in ALF. Therefore, there is a desperate need to establish accurate prognostic models and explore the roles of evolving adjunctive and alternative therapies, such as liver support systems, plasma exchange, stem cells, auxiliary LT, and so on, to enhance transplant-free survival and to fill the void created by the graft shortage.
急性肝衰竭(ALF)是指在无既往肝病的情况下,严重肝损伤导致凝血功能改变和意识障碍的一种状态。ALF病因各异,但其临床特征却极为相似。然而,在临床实践中,全球范围内ALF定义的不一致以及对既往肝病存在情况的混淆引发了诊断难题。过去,ALF的死亡率曾超过80%;然而,近年来由于对病理生理学的深入了解以及重症监护管理的进步,药物治疗的生存率有了显著提高。对乙酰氨基酚相关性ALF的生存率已接近肝移植后的生存率。鉴于肝移植(LT)是一种昂贵的治疗方法,涉及重症患者的大型外科手术和终身免疫抑制,选择可能从中受益的准确患者非常重要。尽管如此,急诊LT对许多ALF患者来说仍然是一种挽救生命的手术。然而,目前的预后模型缺乏一致性,阻碍了及时、精确地选择移植候选者。与ALF患者LT相关的其他问题包括供体短缺、等待名单上出现禁忌证、撤机标准定义模糊、移植前评估的时间限制、伦理问题以及ALF患者移植后相对较差的预后。因此,迫切需要建立准确的预后模型,并探索不断发展的辅助和替代疗法的作用,如肝支持系统、血浆置换、干细胞、辅助性LT等,以提高无移植生存率,并填补供体短缺造成的空白。